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Summary
Background There has been remarkable progress in the treatment of HIV throughout sub-Saharan Africa, but there 
are few data on the prevalence and overlap of other significant causes of disease in HIV endemic populations. Our 
aim was to identify the prevalence and overlap of infectious and non-communicable diseases in such a population in 
rural South Africa.
Methods We did a cross-sectional study of eligible adolescents and adults from the Africa Health Research Institute 
demographic surveillance area in the uMkhanyakude district of KwaZulu-Natal, South Africa. The participants, who 
were 15 years or older, were invited to participate at a mobile health camp. Medical history for HIV, tuberculosis, 
hypertension, and diabetes was established through a questionnaire. Blood pressure measurements, chest x-rays, and 
tests of blood and sputum were taken to estimate the population prevalence and geospatial distribution of HIV, active 
and lifetime tuberculosis, elevated blood glucose, elevated blood pressure, and combinations of these.
Findings 17 118 adolescents and adults were recruited from May 25, 2018, to Nov 28, 2019, and assessed. Overall, 52·1% 
(95% CI 51·3–52·9) had at least one active disease. 34·2% (33·5–34·9) had HIV, 1·4% (1·2–1·6) had active 
tuberculosis, 21·8% (21·2–22·4) had lifetime tuberculosis, 8·5% (8·1–8·9) had elevated blood glucose, and 23·0% 
(22·4–23·6) had elevated blood pressure. Appropriate treatment and optimal disease control was highest for 
HIV (78·1%), and lower for elevated blood pressure (42·5%), active tuberculosis (29·6%), and elevated blood 
glucose (7·1%). Disease prevalence differed notably by sex, across age groups, and geospatially: men had a higher 
prevalence of active and lifetime tuberculosis, whereas women had a substantially high prevalence of HIV at 
30–49 years and an increasing prevalence of multiple and poorly controlled non-communicable diseases when older 
than 50 years.
Interpretation We found a convergence of infectious and non-communicable disease epidemics in a rural South 
African population, with HIV well treated relative to all other diseases, but tuberculosis, elevated blood glucose, and 
elevated blood pressure poorly diagnosed and treated. A public health response that expands the successes of the HIV 
testing and treatment programme to provide multidisease care targeted to specific populations is required to optimise 
health in such settings in sub-Saharan Africa.
Funding Wellcome Trust, Bill & Melinda Gates Foundation, the South African Department of Science and Innovation, 
South African Medical Research Council, and South African Population Research Infrastructure Network.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction 
15 years after massive public health efforts to increase 
access to antiretroviral therapy across sub-Saharan Africa, 
the rate of HIV-associated mortality is dropping and life 
expectancy is rising.1,2 This shift and ongoing demographic 
transitions from largely rural to more urban and sedentary 
lifestyles are increasing risk factors for cardiovascular 
and metabolic non-communicable diseases across the 
continent.3 Consequently, integrated strategies to prevent 
and treat HIV that also address other causes of disease, 
including tuberculosis and non-communicable diseases, 
are of increasing priority.4–6 Multimorbidity, defined as 
multiple medical conditions occurring simultaneously in 
a single individual, is increasing globally.7 Data on the 
patterns, joint risk factors, and outcomes of multimorbidity 
across sub-Saharan African populations are few because 
many cohorts in the region are either hospital-based 
or clinic-based, or because these data focus on specific 
diseases or demographic subpopulations.8,9–11 The success-
ful design of public health programmes requires a clear 
understanding of the effect and interaction of multiple 
infectious and chronic conditions.
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Our aim was to measure the prevalence and overlap 
of four common and treatable infectious and non-
communicable diseases in an HIV endemic population. 
Additionally, we aimed to establish the degree to which 
individual diseases and multimorbidity were diagnosed 
and optimally managed in the population. To do so, we 
created a new research programme, Vukuzazi (“wake up 
and know ourselves” in isiZulu), leveraging an existing 
demographic and health surveillance cohort that has 
yielded substantial information about HIV transmission 
and epidemic dynamics over the past 20 years.12,13 We 
did community-based disease phenotyping for HIV, 
tuberculosis, elevated blood pressure, and elevated 
blood glucose, and analysed demographic and geospatial 
patterns of multimorbidity to inform future public 
health and scientific priorities in HIV endemic African 
populations.
Methods 
Study setting and recruitment 
Eligible adolescent and adult residents, aged 15 years 
or older, from the Africa Health Research Institute demo-
graphic surveillance area in the uMkhanyakude district of 
KwaZulu-Natal, South Africa (figure 1, appendix 2 p 7) 
were invited to participate in this cross-sectional survey 
over an 18-month period (from May 25, 2018, to 
Nov 28, 2019). The district is typical of rural South Africa, 
with approximately 100% of individuals of Black African 
descent, 58% of adults unemployed, and 66% with 
access to piped water in their home (appendix 2 p 7).14 
The University of KwaZulu-Natal Biomedical Research 
Ethics Committee, the London School of Hygiene & 
Tropical Medicine Ethics Committee, and the Partners 
Institutional Review Board approved the study protocol. 
All participants provided informed consent.
Research in context
Evidence before this study
Across sub-Saharan Africa, mortality related to HIV is dropping 
because of widespread antiretroviral therapy use over the last 
15 years. This change is driving increasing life expectancy and 
decreasing rates of tuberculosis. However, morbidity and 
mortality from non-communicable diseases, including 
cardiovascular disease, diabetes, and chronic post-tuberculosis 
lung disease, are rising in the region. In this context, there is an 
increasing concern about the effect of multimorbidity or the 
overlap of two or more chronic conditions on health in African 
settings. Data from large systematic sources, including the 
Global Burden of Disease studies, have shown these trends. 
More granular and localised data are available through health 
systems data, but these sources do not capture members of the 
population who have not accessed the health system. Large 
population-based studies of HIV and non-communicable 
diseases in Kenya, Uganda, and Karonga, Malawi, have shown 
the high prevalence of uncontrolled high blood pressure and 
diabetes in populations with a high HIV prevalence. To date, 
population-based surveys that include the characterisation of 
HIV and non-communicable disease in South Africa, the country 
with the world’s largest HIV epidemic, have been limited to 
either specific conditions or specific age categories, or have not 
included tuberculosis. To inform the design of the protocol, we 
searched PubMed for original reports or reviews using the search 
terms “HIV” OR “HIV infections”, “TB” OR “tuberculosis”, 
“noncommunicable diseases”, “Africa”, and “multimorbidity” 
(search done between Nov 1, 2016, and April 27, 2017).
Added value of this study
In a population in rural KwaZulu-Natal, South Africa that has 
been under continuous demographic surveillance for 20 years, 
we used mobile health camps to measure blood pressure, 
glycosylated haemoglobin, HIV serology, and HIV viral load, and 
used a digital chest x-ray and sputum tests for Mycobacterium 
tuberculosis, to simultaneously define HIV, active and lifetime 
tuberculosis, elevated blood glucose, and elevated blood 
pressure in more than 17 000 adolescents and adults. On the 
basis of knowledge of the underlying population structure, we 
estimated age-specific and sex-specific population prevalence 
rates of each disease, the extent to which each disease was 
optimally diagnosed and treated, and the prevalence of 
multimorbidity using a scale that combined the number of 
simultaneous diseases and their state of control. Geospatial and 
lifespan analysis of individual diseases and multimorbidity 
showed distinct prevalence patterns for HIV and 
multimorbidity.
Implications of all the available evidence
In this population and others in sub-Saharan Africa, although 
HIV diagnosis and the uptake of antiretroviral therapy has not 
reached the Joint United Nations Programme on HIV and AIDS’s 
90–90–90 goals (that by 2020, 90% of individuals positive for 
HIV will be diagnosed, 90% of individuals diagnosed will be on 
antiretroviral therapy, and 90% of people on antiretroviral 
therapy will be virally suppressed), the majority of HIV-positive 
individuals are on effective chronic treatment. In contrast, most 
people with active tuberculosis, elevated blood pressure, and 
elevated blood glucose have undiagnosed or suboptimally 
treated disease. Women bear a particularly high burden of HIV, 
elevated blood pressure, and elevated blood glucose. Men have 
higher rates of active and lifetime tuberculosis, putting them at 
risk for chronic lung disease. In the absence of a rapid 
improvement of public health systems to prevent, diagnose, 
and treat these diseases, the burden of multimorbidity will 
worsen as the cohort of men and women with the highest rates 
of HIV infection (currently in their fourth and fifth decades of 
life) get older over the next several decades. Population-based 
studies of the convergence of infectious and 
non-communicable diseases are needed to inform the design of 
interventions to address multimorbidity in sub-Saharan Africa 
and other low-income and middle-income settings.
Articles
www.thelancet.com/lancetgh   Vol 9   July 2021 e969
Field and laboratory procedures
Individuals were visited at their homes (located using 
the geo-coordinates of their home) and invited to 
participate at a mobile health camp that moved through 
the study area during the study period. At the 
camp, research nurses administered questionnaires 
to assess the individual’s history of HIV, tubercu-
losis, hypertension, and diabetes and to establish the 
presence of tuberculosis symptoms. Anthropometric 
and blood pressure measurements were done using 
the WHO STEPS protocol.15 Blood was obtained for 
measurement of glycosylated haemoglobin (glycated 
haemoglobin [HbA1c], measured using the VARIANT II 
TURBO Haemoglobin testing system [Bio-Rad, Marnes-
la-Coquette, Paris, France]) and for HIV (Genscreen 
Ultra HIV Ag-Ab enzyme immunoassay [Bio-Rad]). 
Participants with a positive HIV immuno assay had a 
reflex HIV-1 RNA viral load test done (Abbott RealTime 
HIV-1 Viral Load [Abbott, IL, USA]). All non-pregnant 
participants were screened for tuberculosis with a 
digital chest x-ray. Sputum was obtained from 
participants reporting tuberculosis symp toms, all 
pregnant women, and all participants whose lung fields 
were abnormal on a chest x-ray, as established by real-
time computer-assisted image analysis or by an 
experienced central radiologist,16,17 and tested for 
Mycobacterium tuberculosis with an Xpert MTB/RIF 
Ultra test (Cepheid, Sunnyvale, CA, USA) and liquid 
mycobacterial culture (BACTEC MGIT 960 System 
[Becton Dickinson, Berkshire, UK]).
Definition of diseases, disease control, and 
multimorbidity 
Medical history and study measurements were used to 
define the presence of each of the four diseases and 
whether the disease was controlled (defined as diagnosed 
and optimally managed). Participants with a positive 
HIV immunoassay were defined as having HIV, and as 
having controlled disease if they were on antiretroviral 
therapy and had an HIV-1 RNA viral load of less than 
40 copies per mL. Active tuberculosis was defined in 
those with sputum positive for M tuberculosis by Xpert 
MTB/RIF Ultra or liquid mycobacterial culture or those 
actively on tuberculosis treatment at the time of the 
survey, or both. Active tuberculosis was defined as 
controlled in participants who had started tuberculosis 
treatment before enrolment in Vukuzazi. Lifetime 
tuberculosis was defined as active tuberculosis, a history 
of tuberculosis treatment, or radiological evidence of 
previous tuberculosis as assessed by the radiologist, or a 
combination. Elevated blood pressure was defined as a 
mean systolic blood pressure of 140 mm Hg or more, 
diastolic blood pressure of 90 mm Hg or more at 
the Vukuzazi health camp, or having been previously 
diagnosed with hypertension and having taken anti-
hypertensive medicines in the 2 weeks before enrolment. 
Figure 1: Participation in the Vukuzazi study
Individuals aged 15 years or older and living in the Africa Heath Research Institute Demographic and Health Surveillance area were eligible for Vukuzazi. The flow chart 
shows the rates of contact by the research team, acceptance of an invitation to Vukuzazi, enrolment at the mobile health camp, and participation in the study 
components required to define four common and treatable diseases (HIV, tuberculosis, elevated blood pressure, and elevated blood glucose).
17 118 completed health history and 
symptom  questionnaires
(100% of enrolled, 49% of 
eligible)
17 114 completed blood pressure 
measurement (100% of 
enrolled, 49% of eligible)
17 118 enrolled (49% of eligible)
25 598 accepted invitation (74% of eligible)
26 460 contacted (76% of eligible)
34 721 eligible
8261 not contacted (24% of eligible)
17 047 completed venepuncture for 
HIV and blood glucose 
testing  (100% of enrolled, 
49% of eligible)
16 991 completed chest x-ray or 
sputum microbiology, or 
both, for tuberculosis testing 
(99% of enrolled, 49% of 
eligible)
862 refused invitation (2% of eligible)
8480 did not attend (24% of eligible)
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Of those who had taken anti-hypertensive medicines, 
those with a mean systolic blood pressure of less than 
140 mm Hg and diastolic blood pressure of less than 
90 mm Hg at the Vukuzazi health camp were defined as 
having controlled disease.18 Elevated blood glucose was 
defined as an HbA1c of 6·5% or more, or having been 
previously diagnosed and having taken hypoglycaemic 
medicines in the 2 weeks before enrolment. Of those 
who had taken hypoglycaemic medicines, those with an 
HbA1c of 6·5% or less were defined as having controlled 
disease.19 We constructed a multimorbidity scale that 
combined the control states of each of the four diseases 
(HIV, active tuberculosis, elevated blood pressure, and 
elevated blood glucose) to categorise participants into 
five states that ranged from healthiest to least healthy: 
(1) free of all measured diseases, (2) the presence of 
one controlled disease, (3) the presence of two or more 
controlled diseases, (4) the presence of one uncontrolled 
disease, and (5) the presence of two or more diseases, at 
least one of which was uncontrolled.
Statistical analysis
Prevalence and 95% CIs for each of the diseases, 
their states of control, and multimorbidity categories 
were calculated overall and by sex and age groups. The 
age groups were 15–24, 25–44, 45–64, and ≥65 years. 
To account for the non-response of eligible members, 
estimates were weighted with the use of inverse 
probability weights, calculated as the inverse probability 
of participation by sex and age group. Continuous 
surface maps of disease and multimorbidity prevalence 
were generated with the use of a standard Gaussian 
kernel interpolation method (with a search radius of 
3 km), which has been extensively used and validated in 
this population for mapping multiple HIV outcomes.20,21 
Analyses were done and some figures produced in R 
statistical software version 4·0·3 and the tidyverse 
package version 1·3·0. Additional figures were produced 
using Stata version 15·1·620 and maps were created 
using ArcGIS by Environmental Systems Research 
Institute version 10·5.
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report.
Results
A total of 17 118 individuals enrolled in Vukuzazi and 
17 047 individuals completed all the study components 
required to define the four diseases and multimorbidity 
(figure 1). Women outnumbered men in the underlying 
population structure (appendix 2 p 9) and enrolled at 
higher rates across all age groups (table, appendix 2 p 10). 
Most participants resided in rural or peri-urban areas 
and the rate of unemployment among those in the labour 
force was high (table). Vukuzazi participants were older, 
more likely to be female, less highly educated, and had 
lower rates of employment than eligible non-participants 
(appendix 2 p 11).
Among the four diseases assessed, HIV had the highest 
overall population prevalence (34·2%, 95% CI 33·5–34·9; 
table). Active tuberculosis was defined in 1·4% (1·2–1·6), 
lifetime tubercu losis in 21·8% (21·2–22·4), elevated 
blood pressure in 23·0% (22·4–23·6) and elevated blood 
glucose in 8·5% (8·1–8·9) of the population. HIV, 
elevated blood pressure, and elevated blood glucose 
were more common in women than in men, whereas 
active and lifetime tuberculosis were more common in 
men (table). HIV prevalence peaked in women aged 
25–44 years, among whom more than half the population 
was infected (62·4%, 95 CI 60·8–63·9; figure 2A). In 
contrast, lifetime tuberculosis (figure 2B), elevated blood 
glucose (figure 2C), and elevated blood pressure 
(figure 2D) all increased with age in both men and 
All (n=17 118) Men (n=5500) Women (n=11 618)
Age group (years)
15–24 4684 (27%) 2101 (38%) 2583 (22%)
25–44 5644 (33%) 1711 (31%) 3933 (34%)
45–64 4393 (26%) 1096 (20%) 3297 (28%)
≥65 2397 (14%) 592 (11%) 1805 (16%)
Residence location
Urban 946 (6%) 292 (5%) 654 (6%)
Peri-urban 5509 (32%) 1820 (33%) 3689 (32%)
Rural 10 571/17 026 (62%) 3361/5473 (61%) 7210/11 553 (62%)
Employment status
Unemployed* 3653/6516 (56%) 1169/2307 (51%) 2484/4209 (59%)
Diseases†
HIV‡ 34·2% (33·5–34·9) 24·8% (23·7–26·0) 40·0% (39·1–40·9)
Active tuberculosis§ 1·4% (1·2–1·6) 1·8% (1·5–2·2) 1·1% (1·0–1·3)
Lifetime tuberculosis¶ 21·8% (21·2–22·4) 23·4% (22·3–24·5) 20·8% (20·1–21·6)
Elevated blood glucose|| 8·5% (8·1–8·9) 4·9% (4·4–5·5) 10·7% (10·1–11·2)
Elevated blood pressure** 23·0% (22·4–23·6) 16·5% (15·5–17·4) 27·0% (26·2–27·8)
Multimorbidity††
Healthy, no disease 47·9% (47·2–48·7) 61·3% (60·0–62·6) 38·5% (37·6–39·4)
One controlled disease 23·9% (23·3–24·6) 15·1% (14·2–16·1) 30·1% (29·3–31·0)
Two or more controlled diseases 2·3% (2·1–2·5) 1·1% (0·9–1·4) 3·1% (2·8–3·5)
One uncontrolled disease 16·4% (15·8–17·0) 16·3% (15·4–17·3) 16·4% (15·8–17·1)
Two or more diseases, at least 
one of which was uncontrolled
9·5% (9·1–9·9) 6·1% (5·5–6·7) 11·9% (11·3–12·5)
Data shown as n (%) or prevalence (95% CI). *Unemployment calculated among members of the resident population 
in the labour force (n=6516). †Prevalence weighted for non-response; weights calculated as the inverse probability of 
survey participation, in strata defined by age group and sex. ‡HIV defined as a positive fourth generation antigen–
antibody test. §Active tuberculosis defined as Vukuzazi sputum positive for Mycobacterium tuberculosis (by either 
GeneXpert Ultra or liquid culture, or both) or currently on treatment for clinically diagnosed tuberculosis, or both. 
¶Lifetime tuberculosis defined by a combination of active tuberculosis, self-reported current or past tuberculosis 
treatment, or radiological findings of previous tuberculosis disease on survey chest x-ray. ||Elevated blood glucose 
defined as a Vukuzazi glycated haemoglobin of 6·5% or more, or diagnosed with and on treatment for diabetes, or 
both. **Elevated blood pressure defined as an average systolic blood pressure of 140 mm Hg or more or an average 
diastolic blood pressure of 90 mm Hg or more in the last two readings on Vukuzazi, or diagnosed with and on 
treatment for hypertension, or a combination. ††Multimorbidity defined by the number and state of control for four 
diseases (HIV, active tuberculosis, elevated blood glucose, and elevated blood pressure).
Table: Population characteristics, disease prevalence, and multimorbidity
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women. Geospatial analysis showed the highest HIV 
prevalence in the southeastern region of the surveillance 
area, a peri-urban area that borders a national highway 
(figure 2A). Geospatial areas with highest prevalence of 
lifetime tuberculosis, elevated blood glucose, and elevated 
blood pressure showed little overlap with the area with 
highest prevalence of HIV (figure 2B–D).
Among the four diseases, HIV had the highest rate 
of disease control, with the majority of participants 
who were HIV positive having an undetectable HIV-1 
RNA viral load (78·1% [4526/5796], appendix 2 p 13). 
The 21·9% (1270/5796) of participants with uncontrolled 
disease included individuals newly diagnosed or not 
yet on antiretroviral therapy (12·9% [750/5796]) and 
those with detectable viraemia despite active ant-
iretroviral therapy (9·0% [520/5796]). In contrast to HIV, 
the other three diseases had much lower rates of optimal 
disease control. Only 42·5% (1866/4395) of people with 
elevated blood pressure had well controlled disease, 
29·6% (69/233) of people with active tuberculosis had 
been diagnosed and were receiving anti-tuberculosis 
treatment, and only 7·1% (117/1652) of those with 
elevated blood glucose had well controlled disease. 
Patterns of uncontrolled disease differed across sex and 
age groups, with the highest rates of uncontrolled HIV 
among men and women younger than 50 years 
(figure 3A), the highest rates of uncontrolled tuberculosis 
among men older than 50 years (figure 3B), and the 
highest rates of uncontrolled elevated blood glucose and 
blood pressure among men and women older than 
50 years (figures 3C, D).
Multimorbidity analysis showed that 52·1% (95% CI 
51·3–52·9) of the population had at least one active 
disease, 23·9% (23·3–24·6) had one disease that 
was optimally controlled, 2·3% (2·1–2·5) had two or 
more diseases all of which were optimally controlled, 
16·4% (15·8–17·0) had one disease that was not optimally 
controlled, and 9·5% (9·1–9·9) had two or more diseases 
at least one of which was not optimally controlled (table, 
figure 3E, appendix 2 p 12). The healthiest state (zero 
diseases) was more frequent in men than women, 
whereas the least healthy state (the presence of two or 
more diseases, at least one of which was uncontrolled) 
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Figure 2: Population prevalence and spatial distribution of communicable and non-communicable diseases in rural KwaZulu-Natal, South Africa
Population prevalence estimates by sex and age category (years) shown in the graphs, and continuous surface maps of the demographic surveillance area showing areas of lowest (blue) and highest 
(red) prevalence for HIV (A), lifetime tuberculosis (B), elevated blood glucose (C), and elevated blood pressure (D).
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Geospatial analysis identified two areas in the southeast 
and southwest of the demographic surveillance area with 
the highest prevalence of uncontrolled multimorbidity 
(figure 3F); notably, the southeastern area overlapped 
with the peri-urban area with highest HIV prevalence 
and the southwestern area corresponded to one of the 
most rural and least accessible parts of the demographic 
surveillance area. Granular visualisations of the four 
diseases illustrated the contribution of each disease and 
its state of control to multimorbidity over the adult 
lifespan (ages 15–90 years) of women (figure 4A) and 
men (figure 4B). Driven primarily by the HIV prevalence 
among women aged 30–40 years (67·5%, [95% CI 
65·5–69·5]), by the age of 30 only 27·4% (25·5–29·4) of 
women were free from all four diseases. Despite their 
high prevalence, most of the diseases in women aged 
30–50 years were controlled. In those older than 50 years, 


























































































E Multimorbidity F Two or more uncontrolled diseases
D Elevated blood pressure
Uncontrolled HIV (viraemic)
Treated HIV (undetectable viraemia)
HIV negative
Undiagnosed active tuberculosis
Diagnosed active tuberculosis, on treatment
No active tuberculosis
Uncontrolled elevated blood glucose
Diagnosed and controlled diabetes




Uncontrolled elevated blood pressure
Diagnosed and controlled hypertension
No elevated blood pressure
One uncontrolled disease
Two uncontrolled diseases







Figure 3: Disease control and multimorbidity
Population prevalence of uncontrolled and controlled (A) HIV, (B) active tuberculosis, (C) elevated blood glucose, (D) elevated blood pressure, (E) multimorbidity by 
sex and age categories, and (F) a continuous surface map of the demographic surveillance area showing areas of lowest (blue) and highest (red) prevalence of the 
highest degree of multimorbidity (ie, the presence of two or more diseases, at least one of which was uncontrolled). M=male participants. F=female participants.
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glucose and elevated blood pressure contributed to high 
amounts of uncontrolled disease and multimorbidity 
(figure 4).
Discussion 
We found a high and overlapping prevalence of 
HIV, tuberculosis, elevated blood glucose, and elevated 
blood pressure in rural South Africa. Instead of the 
classic epidemiological transition in which societies shift 
from predominantly infectious to predominantly non-
communicable burdens of disease over time, in this 
population we observed a convergence of infectious 
and non-communicable disease epidemics. Although 
HIV prevalence was high—with more than a third of the 
entire population and more than half of women aged 
24–44 years positive for HIV— it was well controlled in 
approximately 80% of those affected. In contrast, most 
people with active tuberculosis, elevated blood pressure, 
and elevated blood glucose had disease that was not 
optimally controlled. Our results suggest that, despite 
the success of the HIV programme, the current health-
care system fails to address the burden of multimorbidity 
in this population. Optimisation of population health in 
sub-Saharan Africa will require sustaining excellent HIV 
treatment programmes while strengthening multidisease 
approaches with targeted care for specific demographic 
groups.
Simultaneous measurement and analysis of these 
four common and treatable diseases highlighted the 
particularly heavy burden of disease borne by women 
(figure 4A). Our findings concur with other South African 














































































































































































































Uncontrolled disease Controlled disease No disease
Two or more uncontrolled diseases One uncontrolled diseases Two or more diseases, at least one of which was uncontrolled One controlled disease Healthy, no disease
Age (years) Age (years)
Figure 4: Multimorbidity across the lifespan
Granular visualisation of the individual contributions of controlled or uncontrolled HIV, active tuberculosis, elevated blood glucose, and elevated blood pressure to multimorbidity across the adult 
lifespan of (A) women and (B) men who participated in Vukuzazi.
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rates of HIV, hypertension, and diabetes in women.22,23 
Only in the youngest age strata (adolescents aged 
15–19 years) were more than 80% of women free of 
disease. In this population, between the ages of 15 and 
35 years, women had high HIV incidence, highlighting 
the persistent and urgent need to identify and implement 
interventions to prevent HIV infections.24 Because of the 
remarkably effective HIV care delivery system established 
in the region, more than 80% of women with HIV had an 
undetectable viral load on antiretroviral therapy.25 Yet, 
even as most women emerge from decades of high 
risk of HIV infection or with controlled HIV on life-
long antiretroviral therapy, by the age of 45 years, they 
transition to a period of high risk of comorbid diabetes 
and hypertension. Unlike HIV, these conditions are not 
currently addressed by a robust public health response, 
as shown by more than 64·1% of women older than 
45 years having high blood glucose or high blood 
pressure; 68·4% of them poorly controlled. As such, our 
results support analyses from other South African 
settings in suggesting that the health of older women, in 
particular those who are not engaged in primary care for 
HIV infection, might be comparatively neglected.
Men had lower rates of HIV and non-communicable 
diseases but higher rates of both active and a history of 
tuberculosis. There are many reasons why these data 
should not be interpreted to mean that men have better 
health than women. First, our finding that nearly half of 
men older than 50 years had tuberculosis in their lifetime 
is concerning because there is emerging evidence 
that this is a risk factor for chronic lung disease,26 recurrent 
tuberculosis, and a decreased life expectancy.27 Additionally, 
men participated in Vukuzazi at lower rates than women 
and are known to be less often enrolled in HIV care 
programmes and to have lower life expectancy gains as a 
result.28 Finally, men are also at a greater risk for an early 
death in South Africa because of a higher burden of 
traumatic deaths, and thus our data could be susceptible 
to a survivor bias.29 In addition to highlighting the need to 
better diagnose and address tuberculosis and its sequelae 
in men, our results reinforce the need for novel delivery 
platforms to engage men in both health care and research 
to improve understanding of their health priorities.
The convergence of infectious and non-communicable 
disease epidemics poses notable challenges to the public 
health system. Despite calls to address the challenge 
of multimorbidity earlier in the course of the world’s 
largest HIV epidemic, in South Africa and other 
countries in the same region, progress in establishing 
an excellent antiretroviral treatment programme in the 
public sector has outpaced that of diagnosing and 
treating chronic non-communicable diseases or fully 
integrating tuberculosis and HIV care.30,31 Our findings 
suggest that the successes of the HIV care delivery 
system should be harnessed and applied to an integrated 
multidisease approach. Simultaneous epidemics that 
require lifelong treatments call for creative solutions 
that make use of non-traditional and community-based 
care systems to extend the reach of the health-care 
system.32 Approaches that include task-shifting to nurses 
and community health workers and integrating the 
management of multiple diseases have shown promise 
but require optimisation.33,34 Decen tralising care has the 
additional benefit of reducing clinic-based services and 
protecting individuals at a high risk of nosocomial 
exposures and complications in the face of emerging 
data from the COVID-19 pandemic, showing that poorly 
controlled multimorbidity predisposes indi viduals to 
additive morbidity and mortality risk. In addition, the 
health-care system needs to be able to provide access to 
the most vulnerable and those poorly engaged by 
conventional systems, including men and those residing 
in remote, rural areas.
The prevention of multimorbidity will require an 
improved understanding of the specific causal deter-
minants of individual and overlapping diseases. Trans-
disciplinary research will be required to understand 
and address the contrasting demographic and geospatial 
distribution of infectious and non-communicable diseases, 
which might be influenced by biological, environmental, 
social, and health systems factors. Factors specific to 
sub-Saharan Africa, including the combined effects of 
childhood malnutrition, adult obesity, and high rates of 
maternal HIV infection, might have a unique effect on the 
long-term cardiometabolic health of the population.8 
Although Africa has the highest genetic diversity of any 
continent and bears a disproportionate and unique burden 
of disease, it is under-represented among cohorts that 
assemble large multidimensional data and biorepositories 
to support modern genetic and molecular methods to 
advance public health.35,36 The clinical, phenotypic, and 
geo graphical data presented here are nested within a 
longitudinal demographic surveillance cohort that has 
more than 15 years of individual and household structure 
data, which will allow for the spatially organised analysis of 
disease transmis sion and environmental exposures. The 
data presented here are augmented by a bio repository of 
over 250 000 biosamples that were collected and stored 
from more than 99% of the participants. The integrated 
analyses of genetic, biological, and social determinants 
of the four diseases measured here and the population 
health outcomes that will be assessed during ongoing 
demographic and health surveillance activities will 
enhance the understanding of current and emerging 
diseases, and allow for the emulation of scientific discovery 
similar to that of the UK BioBank and Framingham36,37 in a 
rural South African population.
There are several limitations to our approach. Although 
we report a high rate of enrolment for a population-
based multidisease study,38 non-systematic non-response, 
including lower rates of enrolment by men, might have 
resulted in bias during the data collection and skewed 
results. As is standard for population screening studies, 
we defined elevated blood pressure and blood glucose 
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based on measurements done on a single day; additional 
longitudinal measurements are needed to establish 
diagnoses of hypertension and diabetes and clarify 
health system needs. Some of the definitions of disease 
included people with a self-reported history of diabetes, 
hypertension, or tuberculosis, which might incorporate 
diagnostic or reporting bias into our estimates. The 
prevalence of active tuberculosis might have been under-
estimated or overestimated because of the suboptimal 
diagnostic characteristics of sputum microbiological tests. 
Optimal therapeutic blood pressure and HBA1c targets 
for anti-hypertensive and anti-hyperglycaemic treatments 
are topics of active investigation. For the purpose of 
this study, and to allow comparison between the four 
diseases, we defined optimal disease control using 
standard targets for blood pressure control and for people 
with newly diagnosed diabetes; however, the consideration 
of alternative targets for specific subpopulations (ie, people 
with other cardiac risk factors or older individuals) 
would be necessary to inform the design of interventional 
strategies. We assessed four common and treatable 
diseases in this study; however, important categories of 
disease, including cancer, chronic respiratory disease, 
mental health, and child health, were not measured in 
this study, limiting our ability to draw comprehensive 
conclusions about population health. In this initial effort 
to use mobile health camps to measure multiple diseases 
simultaneously, our selection of diseases was limited by 
practical and ethical considerations, and most importantly 
the need to consider the burden that community screening 
would place on the rural primary health-care system. 
Collaboration with the local and regional department of 
health personnel and across multiple medical disciplines 
was required to devise appropriate referral and treatment 
pathways for each disease measured. In the future, in 
partnership with local and provincial public health 
services, we aim to establish additional structures, thus 
allowing additional important categories of disease to 
be characterised in this population. Finally, the data 
presented are cross-sectional and so do not allow causal 
inference analysis of the effect of these diseases on a 
participant’s eventual morbidity and mortality. Because 
this survey was situated within a demographic and health 
surveillance site that includes ongoing health information 
and verbal autopsy data, we expect to be able to contribute 
additional data on the longitudinal effects of these 
conditions and the effect of health systems interventions 
to ameliorate them in future reports.
In conclusion, we found converging epidemics of 
infectious and non-communicable diseases across the 
lifespan of adults in rural South Africa. Our findings of 
high rates of HIV requiring continuous access to daily 
medication, high rates of undiagnosed tuberculosis, 
low rates of optimally controlled non-communicable 
diseases, and complex patterns of multimorbidity 
highlight just some of the challenges in improving 
health for African populations with multiple intersecting 
epidemics. Our findings call for the development and 
evaluation of targeted public health programmes and 
scalable biomedical innovations to reduce the burden 
of specific diseases and multimorbidity to better 
population health. In the absence of improved disease 
prevention and control interventions, we expect the 
burden of multimorbidity to worsen as the generation of 
men and women most severely affected by the HIV 
epidemic ages over the next several decades. These 
challenges highlight the importance of investing in 
population science to define the interactions between 
infectious and non-communicable diseases and to 
harness the resulting knowledge to develop relevant 
biomedical and public health strategies to improve the 
health of African populations.
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